NRC HEALTH·4

Jun 25, 4:45 PM ET

Berwick Donald M 4

4 · NRC HEALTH · Filed Jun 25, 2026

Research Summary

AI-generated summary of this filing

Updated

NRC Health Director Donald Berwick Receives Restricted Stock Award

What Happened Donald M. Berwick, a director of NRC Health (NRC), was granted 7,697 restricted stock units (RSUs) on 2026-06-23. The Form 4 reports 7,697 shares acquired at $0.00 (award code A); the filing shows $0 as the acquisition cost because this is an equity grant. A footnote clarifies the award represents annual equity compensation equal to $150,000, converted into RSUs based on the closing price the day before the issuer's 2026 annual meeting.

Key Details

  • Transaction date: 2026-06-23; Form 4 filed 2026-06-25 (filed within the standard 2-business-day window).
  • Reported on-form price: $0.00 per share (award); footnote value: $150,000 total grant (converted to 7,697 RSUs).
  • Vesting: Award will vest and become exercisable on the date of the issuer's 2027 annual stockholder meeting, subject to forfeiture and termination provisions.
  • Plan: Granted under the Issuer's 2025 Omnibus Incentive Plan.
  • Shares owned after transaction: not specified in the provided filing.
  • Transaction code: A (award/grant).

Context This was a compensation award (RSUs), not an open-market purchase or sale. RSUs typically convert to shares when they vest and are generally taxable as ordinary income at vesting; they do not directly signal insider buying or selling intent. The filing appears timely and includes a footnote explaining the $150,000 grant conversion.

Insider Transaction Report

Form 4
Period: 2026-06-23
Transactions
  • Award

    Common Stock

    [F1]
    2026-06-23+7,6977,697 total
Footnotes (1)
  • [F1]This share award represents annual equity compensation in the form of a grant of restricted stock units equal to $150,000, divided by the closing price on the date immediately preceding the Issuer's 2026 annual meeting of stockholders, under the Issuer's 2025 Omnibus Incentive Plan. The award will vest and become exercisable on the date of the Issuer's 2027 annual stockholder meeting, subject to vesting, forfeiture, and termination provisions.
Signature
/s/ Donald M. Berwick, by Christopher Kortum, attorney-in-fact, pursuant to a POA previously filed with the SEC|2026-06-25

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4